Logo image of BDTX

BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Fundamental Analysis

NASDAQ:BDTX - Nasdaq - US09203E1055 - Common Stock - Currency: USD

2.17  +0.06 (+2.84%)

After market: 2.16 -0.01 (-0.46%)

Fundamental Rating

3

Taking everything into account, BDTX scores 3 out of 10 in our fundamental rating. BDTX was compared to 561 industry peers in the Biotechnology industry. BDTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BDTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BDTX was profitable.
BDTX had a negative operating cash flow in the past year.
BDTX had negative earnings in each of the past 5 years.
BDTX had a negative operating cash flow in each of the past 5 years.
BDTX Yearly Net Income VS EBIT VS OCF VS FCFBDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

BDTX has a Return On Assets (-56.81%) which is comparable to the rest of the industry.
BDTX has a Return On Equity (-83.66%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -56.81%
ROE -83.66%
ROIC N/A
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
BDTX Yearly ROA, ROE, ROICBDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BDTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDTX Yearly Profit, Operating, Gross MarginsBDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

BDTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BDTX has been increased compared to 5 years ago.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BDTX Yearly Shares OutstandingBDTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BDTX Yearly Total Debt VS Total AssetsBDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

BDTX has an Altman-Z score of -5.07. This is a bad value and indicates that BDTX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BDTX (-5.07) is worse than 61.14% of its industry peers.
There is no outstanding debt for BDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.07
ROIC/WACCN/A
WACCN/A
BDTX Yearly LT Debt VS Equity VS FCFBDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.92 indicates that BDTX has no problem at all paying its short term obligations.
The Current ratio of BDTX (4.92) is comparable to the rest of the industry.
A Quick Ratio of 4.92 indicates that BDTX has no problem at all paying its short term obligations.
With a Quick ratio value of 4.92, BDTX perfoms like the industry average, outperforming 54.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.92
Quick Ratio 4.92
BDTX Yearly Current Assets VS Current LiabilitesBDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

BDTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 103.61%, which is quite impressive.
EPS 1Y (TTM)103.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%380%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.04% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.12%
EPS Next 2Y7.38%
EPS Next 3Y0.76%
EPS Next 5Y20.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDTX Yearly Revenue VS EstimatesBDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
BDTX Yearly EPS VS EstimatesBDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 36.17, which means the current valuation is very expensive for BDTX.
Based on the Price/Earnings ratio, BDTX is valued cheaper than 93.58% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.60, BDTX is valued a bit more expensive.
The Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 36.17
Fwd PE N/A
BDTX Price Earnings VS Forward Price EarningsBDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDTX Per share dataBDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.84
PEG (5Y)N/A
EPS Next 2Y7.38%
EPS Next 3Y0.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLACK DIAMOND THERAPEUTICS I

NASDAQ:BDTX (5/20/2025, 8:00:01 PM)

After market: 2.16 -0.01 (-0.46%)

2.17

+0.06 (+2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners97.65%
Inst Owner Change-14.04%
Ins Owners0.94%
Ins Owner Change-60.81%
Market Cap123.00M
Analysts85.45
Price Target13.26 (511.06%)
Short Float %17.2%
Short Ratio2.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.67%
Min EPS beat(2)12.77%
Max EPS beat(2)26.57%
EPS beat(4)4
Avg EPS beat(4)17.32%
Min EPS beat(4)8.83%
Max EPS beat(4)26.57%
EPS beat(8)8
Avg EPS beat(8)14.99%
EPS beat(12)12
Avg EPS beat(12)12.81%
EPS beat(16)14
Avg EPS beat(16)9.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.99%
PT rev (3m)-10.34%
EPS NQ rev (1m)-89.53%
EPS NQ rev (3m)107.25%
EPS NY rev (1m)-28.17%
EPS NY rev (3m)42.09%
Revenue NQ rev (1m)-37.5%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-37.5%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 36.17
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB 1.48
EV/EBITDA N/A
EPS(TTM)0.06
EY2.76%
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0
BVpS1.47
TBVpS1.47
PEG (NY)0.84
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.81%
ROE -83.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.92
Quick Ratio 4.92
Altman-Z -5.07
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.94%
Cap/Depr(5y)323.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)103.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%380%
EPS Next Y43.12%
EPS Next 2Y7.38%
EPS Next 3Y0.76%
EPS Next 5Y20.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.95%
EBIT Next 3Y-0.19%
EBIT Next 5Y23.43%
FCF growth 1Y6.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.62%
OCF growth 3YN/A
OCF growth 5YN/A